Sep 20, 2024
Product Launch
Introducing the Next Generation PCR Testing Platform
CO-DX unveils revolutionary portable PCR system designed for point-of-care testing in various healthcare settings with enhanced speed and accuracy.
Read the article →
Amplify your research with our innovative infectious disease detection products for non-clinical applications.
Choose from a range of CoMira™ Logix Smart® products compatible with most qPCR equipment, which include RNaseP as an internal positive control (IPC).
Multiplex real-time PCR for simultaneous research detection of Influenza A, Influenza B, and SARS-CoV-2 in a single reaction.
Research-use real-time PCR detection of SARS-CoV-2, built on patented Co-Primers™ technology for high specificity.
Research-use real-time PCR assay for the detection of monkeypox (Mpox) virus DNA.
Two-target Mpox assay providing added confidence through dual-gene detection for research use.
Research-use SARS-CoV-2 detection targeting the RdRp and E genes for robust, specific results.
Dual-select research-use SARS-CoV-2 assay engineered to maintain performance against emerging variants.
A safe, high-sensitivity nucleic acid gel stain for research visualization of DNA and RNA.
Get results in minutes instead of hours or days with real-time PCR technology.
Give your research laboratory improved accuracy over antigen and isothermal testing.
Conserve PCR components and consumable goods while you reduce testing time.
Contact us for a full demo of our RUO solutions
Sep 20, 2024
Product Launch
CO-DX unveils revolutionary portable PCR system designed for point-of-care testing in various healthcare settings with enhanced speed and accuracy.
Read the article →Oct 5, 2024
Partnership
CO-DX partners with international health organizations to deploy PCR testing in emerging markets, bringing advanced diagnostics to underserved communities worldwide.
Read the article →Oct 12, 2024
Company News
CO-DX announces FDA EUA approval for its rapid PCR COVID-19 test kit, enabling faster diagnostic testing nationwide and expanding access to reliable molecular diagnostics.
Read the article →